FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

675 letters match. Newest first.

  1. Dr. Joel Kaplan Inc.

    FDA warned Dr. Joel Kaplan Inc. that its sexual health devices are unapproved, misbranded, and made under quality system violations.

    High risk
  2. Deymed Diagnostic s.r.o.

    Deymed Diagnostic s.r.o.'s BrainFeedback Pro, TruScan LT, and DuoMAG NL devices had quality system violations in design, complaints, production, and records.

    Medium
  3. Neitz Instruments Company Ltd.

    FDA warns Neitz Instruments its ophthalmoscope is misbranded because medical device reporting procedures are inadequate.

    Medium
  4. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  5. Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi

    FDA warns Turkish hand sanitizer maker Sudesan of CGMP violations and adulterated drugs.

    High risk
  6. Sonesta Medical AB

    FDA warned Sonesta Medical AB that its radiographic and cystometric tables violated device quality system rules.

    Medium
  7. Fresenius Medical Care AG & Co. KGaA

    FDA warns Fresenius over delayed fixes and reporting for PCB leaching from silicone tubing in hemodialysis machines.

    High risk
  8. Nutra Blend, LLC subsidiary of Land O’Lakes

    Nutra Blend's medicated calf feed contained unintended monensin, killing calves and prompting a recall.

    High risk
  9. Intas Pharmaceuticals Limited

    FDA cited Intas Pharmaceuticals for CGMP violations, including manipulated visual inspection records and inadequate sterile-drug controls.

    High risk
  10. Xiamen Wally Bath Manufacture Co., Ltd.

    FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.

    High risk
  11. Brenntag Great Lakes, LLC

    Brenntag Great Lakes failed to prevent cross-contamination of OTC hand sanitizer made on equipment shared with industrial chemicals.

    High risk
  12. Elemental Herbs Inc. d/b/a ALL good

    Elemental Herbs (ALL good) cited for CGMP failures and unapproved, misbranded Goop Skin Recovery Balm.

    High risk
  13. Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi

    FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.

    High risk
  14. Ming Fai Industrial Co LTD

    Ming Fai Industrial, a Shenzhen device maker, lacked validation and acceptance-status controls for ultrasound gel and probe covers.

    High risk
  15. Acrostak Schweiz AG

    FDA warns Acrostak Schweiz that its M-Cath Flexy Microcatheter was marketed without required 510(k) clearance (FDA marketing permission) and has quality-system violations.

    High risk
  16. Neurotris, Inc. dba A1 Engineering

    FDA warns Neurotris over unapproved, misbranded facial/body stimulator devices and quality system violations.

    High risk
  17. Biorica International Corp.

    FDA warned Biorica International that its Plaquex Oral Dietary Supplement is an unapproved new drug because website claims promote disease treatment and prevention.

    High risk
  18. WAVi Co.

    FDA says WAVi sold its unapproved WAVi Desktop brain-assessment device for clinical use and had quality-system failures.

    High risk
  19. Golden Natural Products

    FDA says Golden Natural Products lacked required foreign supplier safety checks for imported dried fruit and noodles.

    Medium
  20. Antonio E. Blanco, M.D./Vista Health Research, LLC

    FDA cited Dr. Antonio E. Blanco/Vista Health Research for enrolling ineligible trial subjects and missing required safety imaging.

    High risk
  21. Abiomed Inc.

    Abiomed marketed Impella Connect System without PMA and had CGMP, complaint, and MDR reporting failures.

    High risk
  22. Ikal LLC

    FDA warns Ikal LLC that it lacked required foreign supplier verification checks for imported fresh avocados.

    High risk
  23. Luis Javier Pena-Hernandez, M.D., FCCP

    FDA warns Dr. Pena-Hernandez over ineligible subject enrollment and lapsed IRB approval for investigational drugs.

    High risk
  24. Fresenius Kabi AG

    FDA warned Fresenius Kabi’s Fenwal plant in Puerto Rico about unsafe manufacturing of blood-pack units and solutions.

    High risk
  25. PT. Winson Prima Sejahtera

    FDA says PT. Winson Prima Sejahtera's ready-to-eat yellowfin tuna seafood safety plan lacks pathogen and histamine controls.

    High risk
  26. Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.

    FDA warned Moor Herbs that its herbal products are unapproved drugs with disease claims and are made without required supplement quality controls.

    High risk
  27. BYD Precision Manufacture Co., Ltd

    FDA warned BYD Precision Manufacture over quality-system and reporting failures for surgical masks and an N95 respirator made in Shenzhen, China.

    Medium
  28. Del Valle Import & Export 3, Inc. DBA El Progreso Imports

    FDA warns Vernon, CA importer El Progreso Imports that it lacked required foreign supplier verification records for most imported foods.

    Medium
  29. Caltag Medsystems Ltd

    FDA warned Caltag Medsystems over quality-system failures in making TransFix/EDTA Vacuum Blood Collection Tubes.

    Medium
  30. Green Pharmaceutical Co. Ltd.

    FDA warns South Korea's Green Pharmaceutical over OTC drug CGMP failures, including missing identity testing and weak quality unit.

    High risk
  31. Osmosis, LLC

    Osmosis sold unapproved drug products with disease claims and had dietary supplement CGMP and labeling violations.

    High risk
  32. Reckitt/Mead Johnson Nutrition

    FDA warned Reckitt/Mead Johnson over Cronobacter contamination and inadequate process controls at two powdered infant formula plants.

    High risk
  33. Perrigo Wisconsin, LLC

    FDA found Cronobacter in Perrigo infant formula and facility; company recalled some Gerber Good Start Soothe Pro.

    High risk
  34. Cosmobeauti Laboratories & Manufacturing Inc.

    FDA warns Cosmobeauti Laboratories over manufacturing rule violations for OTC sunscreen drugs, including backdated batch records and missing microbial testing.

    High risk
  35. Amor Nino Foods, Inc.

    FDA says Amor Nino Foods' ready-to-eat Hawaiian-style aku tuna sticks were made under an inadequate seafood safety plan and without required monitoring.

    High risk
  36. King Systems Corp. dba Ambu, Inc.

    FDA warns Ambu's King Systems over unapproved King LTS-D airway device and pediatric website claims.

    High risk
  37. K. Boeun Pharmaceutical Co., Ltd.

    K. Boeun Pharmaceutical's OTC drugs were cited for CGMP violations, including missing identity tests for DEG/EG-risk components and inadequate quality unit.

    High risk
  38. International Laboratories Corp. Ltd.

    International Laboratories Corp. Ltd. failed manufacturing-practice rules for OTC drugs, including component identity testing and quality-unit oversight.

    High risk
  39. Integra LifeSciences Corporation

    FDA warned Integra LifeSciences over collagen-based medical devices made in Boston after an inspection found quality-system failures and endotoxin testing problems.

    High risk
  40. Avaria Health & Beauty Corp.

    FDA cites Avaria Health & Beauty for manufacturing-rule violations in OTC drugs, including missing glycerin identity testing and weak quality unit.

    High risk
  41. Suhan Aerosol

    Suhan Aerosol, an Indian OTC drug maker, failed to test high-risk ingredients for toxic diethylene/ethylene glycol and lacked quality oversight.

    High risk
  42. Orchid Lifesciences

    FDA warns Orchid Lifesciences over over-the-counter drug testing gaps and weak quality unit.

    High risk
  43. Baxter Healthcare Corporation

    FDA warned Baxter over CGMP violations at its India plant, including inadequate endotoxin and visual inspection investigations for sterile injectables.

    High risk
  44. Avlon Industries, Inc.

    FDA warned Avlon Industries that its over-the-counter drug manufacturing broke quality rules, citing missing identity tests for high-risk glycerin/propylene glycol and validation failures.

    High risk
  45. LXR Biotech, LLC

    FDA says LXR Biotech, a contract maker of an OTC drug, shipped batches without testing components or finished product.

    High risk
  46. Jamol Laboratories, Inc.

    FDA found Jamol Laboratories making a nasal emollient under insanitary conditions and without adequate quality control, lab testing, or process validation.

    High risk
  47. Porfirios Italian Foods, Inc.

    FDA says Porfirios Italian Foods made pasta under insanitary conditions without a required food safety plan.

    High risk
  48. Wise Women’s Choice

    FDA warned Wise Women’s Choice that its natural birth control cream is an unapproved new drug sold with pregnancy-prevention claims.

    High risk
  49. Baits and Sea Foods, S.A.

    FDA warns Baits and Sea Foods, S.A. over missing histamine, botulinum and allergen controls in mahi-mahi HACCP plan.

    High risk
  50. Stratus Biosystems, LLC dba CellGenuity Regenerative Science

    FDA warns CellGenuity over unapproved amniotic/umbilical products and serious sterility failures.

    High risk